IL33 Is a Stomach Alarmin That Initiates a Skewed Th2 Response to Injury and Infection

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 2, 2015, Pages 203-221.e3

  Buzzelli, Jon N ^a,b   Chalinor, Heather V ^a   Pavlic, Daniel I ^a   Sutton, Philip ^a,b   Menheniott, Trevelyan R ^a   Giraud, Andrew S ^a,b   Judd, Louise M ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Gastric Cancer; Helicobacter pylori; IL33; Inflammatory Response

Indexed keywords

ACETYLSALICYLIC ACID; CELL MARKER; INTERLEUKIN 33; INTERLEUKIN RECEPTOR; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 5AC; RECEPTOR INTERLEUKIN 1 RECEPTOR LIKE 1; STAT3 PROTEIN; ULEX EUROPAEUS 1; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; BIOPSY; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; INFLAMMATION; LYMPHOID CELL; METAPLASIA; MOUSE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH DISEASE; STOMACH INJURY; STOMACH MUCOSA; STOMACH SECRETION; TH2 CELL;

EID: 84928939761     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2014.12.003     Document Type: Article

References (49)

1. Oppenheim J.J., Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005, 17:359-365.
2. Arshad M.I., Piquet-Pellorce C., Samson M. IL-33 and HMGB1 alarmins: sensors of cellular death and their involvement in liver pathology. Liver Int 2012, 32:1200-1210.
3. Schmitz J., Owyang A., Oldham E., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
4. Neill D.R., Wong S.H., Bellosi A., et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010, 464:1367-1370.
5. Pecaric-Petkovic T., Didichenko S.A., Kaempfer S., et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009, 113:1526-1534.
6. Smithgall M.D., Cormeau M.R., Yoon B.R., et al. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008, 20:1019-1030.
7. Suzukawa M., Koketsu R., Iikura M., et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 2008, 88:1245-1253.
8. Balato A., Lembo S., Mattii M., et al. IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol 2012, 21:892-894.
9. Duan L., Chen J., Zhang H., et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol Med 2012, 18:753-761.
10. Grob P., Doser K., Falk W., et al. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis 2012, 18:1900-1909.
11. Humphreys N.E., Xu D., Hepworth M.R., et al. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. JImmunol 2008, 180:2443-2449.
12. Wills-Karp M., Rani R., Dienger K., et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. JExp Med 2012, 209:607-622.
13. Howlett M., Chalinor H.V., Buzzelli J.N., et al. IL-11 is a parietal cell cytokine that induces atrophic gastritis. Gut 2012, 61:1398-1409.
14. Judd L.M., Alderman B.M., Howlett M., et al. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology 2004, 126:196-207.
15. Jackson C.B., Judd L.M., Menheniott T.R., et al. Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression. JPathol 2007, 213:140-151.
16. Jones L.A., Roberts F., Nickdel M.B., et al. IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur J Immunol 2010, 40:426-436.
17. Pichery M., Mirey E., Mercier P., et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. JImmunol 2012, 188:3488-3495.
18. Meeroff J.C., Paulsen G., Guth P.H. Parenteral aspirin produces and enhances gastric mucosal lesions and bleeding in rats. Am J Dig Dis 1975, 20:847-852.
19. Peterson A.J., Menheniott T.R., O'Connor L., et al. Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans. Gastroenterology 2010, 139:2005-2017.
20. Li D., Guabiraba R., Besnard A.G., et al. IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. JAllergy Clin Immunol 2014, 134:1422-1432.
21. Judd L.M., Bredin K., Kalantzis A., et al. STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology 2006, 131:1073-1085.
22. Liu H., Wu X., Wang S., et al. Invitro repolarized tumor macrophages inhibit gastric tumor growth. Oncol Res 2013, 20:275-280.
23. Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011, 11:750-761.
24. Shang Y., Kakinuma S., Amasaki Y., et al. Aberrant activation of interleukin-9 receptor and downstream Stat3/5 in primary T-cell lymphomas invivo in susceptible B6 and resistant C3H mice. InVivo 2008, 22:713-720.
25. Yamasaki A., Saleh A., Koussih L., et al. IL-9 induces CCL11 expression via STAT3 signalling in human airway smooth muscle cells. PLoS One 2010, 5:e9178.
26. Butcher B.A., Kim L., Panopoulos A.D., et al. IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF-alpha in host macrophages. JImmunol 2005, 174:3148-3152.
27. Schiering C., Krausgruber T., Chomka A., et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014, 513:564-568.
28. Ma G.F., Miao Q., Liu Y.M., et al. High FoxP3 expression in tumour cells predicts better survival in gastric cancer and its role in tumour microenvironment. Br J Cancer 2014, 110:1552-1560.
29. Fox J.G., Beck P., Dangler C.A., et al. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy. Nat Med 2000, 6:536-542.
30. Holcombe C. Helicobacter pylori: the African enigma. Gut 1992, 33:429-431.
31. Farrell J.J., Taupin D., Koh T.J., et al. TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. JClin Invest 2002, 109:193-204.
32. Xue L., Aihara E., Podolsky D.K., et al. Invivo action of trefoil factor 2 (TFF2) to speed gastric repair is independent of cyclooxygenase. Gut 2010, 59:1184-1191.
33. Kurt-Jones E.A., Cao L., Sandor F., et al. Trefoil family factor 2 is expressed in murine gastric and immune cells and controls both gastrointestinal inflammation and systemic immune responses. Infect Immun 2007, 75:471-480.
34. Sun P., Ben Q., Tu S., et al. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 2011, 56:3596-3601.
35. Ohto-Ozaki H., Kuroiwa K., Mato N., et al. Characterization of ST2 transgenic mice with resistance to IL-33. Eur J Immunol 2010, 40:2632-2642.
36. Fitzgerald R.C., Abdalla S., Onwuegbusi B.A., et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002, 51:316-322.
37. Csendes A., Smok G., Cerda G., et al. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Dis Esophagus 1997, 10:38-42.
38. Kao S.S., Chen W.C., Hsu P.I., et al. The frequencies of gastroesophageal and extragastroesophageal symptoms in patients with mild erosive esophagitis, severe erosive esophagitis, and Barrett's esophagus in Taiwan. Gastroenterol Res Pract 2013, 2013:480325.
39. Rubenstein J.H., Inadomi J.M., Scheiman J., et al. Association between Helicobacter pylori and Barrett's esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol 2014, 12:239-245.
40. Walker J.A., Barlow J.L., McKenzie A.N. Innate lymphoid cells-how did we miss them?. Nat Rev Immunol 2013, 13:75-87.
41. Fallon P.G., Ballantyne S.J., Mangan N.E., et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. JExp Med 2006, 203:1105-1116.
42. Dundar E., Oner U., Peker B.C., et al. The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma. JInt Med Res 2008, 36:88-95.
43. Stebbins K.J., Broadhead A.R., Baccei C.S., et al. Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lung. JPharmacol Exp Ther 2010, 332:764-775.
44. Carus A., Ladekarl M., Hager H., et al. Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. Lung Cancer 2013, 81:130-137.
45. Galdiero M.R., Bonavita E., Barajon I., et al. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013, 218:1402-1410.
46. Bu X.N., Zhou Q., Zhang J.C., et al. Recruitment and phenotypic characteristics of interleukin 9-producing CD4+ T cells in malignant pleural effusion. Lung 2013, 191:385-389.
47. Purwar R., Schlapbach C., Xiao S., et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012, 18:1248-1253.
48. Mowat A.M., Bain C.C. Mucosal macrophages in intestinal homeostasis and inflammation. JInnate Immun 2011, 3:550-564.
49. Tebbutt N.C., Giraud A.S., Inglese M., et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002, 8:1089-1097.